Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported purchases exceed sales by $2.3MOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
Company profile
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Mosseri Marlio Charles |
| 10% Owner |
| Jun 30 '26 |
| Buy |
| $18.32 |
| 50,000 |
| $916,000 |
| 3,186,576 |
| Jul 01 01:41 PM |
| Bentsur Ron | Chairman & CEO | Jun 30 '26 | Buy | $20.00 | 12,500 | $250,000 | 3,688,424 | Jul 01 01:39 PM |
| Bentsur Ron | Chairman & CEO | Nov 05 '25 | Buy | $5.72 | 5,000 | $28,600 | 3,525,924 | Nov 06 08:01 AM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.